Table 2.
Phase I/II and phase II studies (ongoing or published) evaluating the effect of rapalogs in combination with anti-CD20 or anti-CD20-based therapies.
| Disease | Therapeutic regimen | Trial phase | Nbe of patients in the cohort | ORR (%) | CR (%) | DR (months) | State of the study | Reference | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Rapalog | anti-CD20 | chemotherapeutic agents | ||||||||
| MCL | Temsirolimus | Rituximab | None | II | 69 | 59 | 13 | 5.4 months (R-refractory) 10.9 months (R-sensitive) | published | (136) |
| DLBCL | Everolimus | Rituximab | none | II | 24 | 38 | 12.5 | 8.1 months | published | (137) |
| MCL, CLL/SLL, DLBCL, Hodgkin's disease | Everolimus | Rituximab | none | II | 49 | - | - | - | active | NCT01665768 |
| DLBCL | Temsirolimus | Rituximab | DHAP | II | 88 | - | - | - | active | NCT01653067 |
| MCL, FL | Temsirolimus | Rituximab | Bendamustine | I/II | 39 | - | - | - | completed | NCT01078142 |
MCL, Mantle Cell Lymphoma; DLBCL, Diffuse Large B Cell Lymphoma; FL, Follicular Lymphoma; CLL, Chronic Lymphocytic Leukemia; SLL, Small Lymphocytic Lymphoma; DHAP, Dexamethasone, High dose Ara-C and Platinol (cisplatin); ORR, overall response rate; CR, complete response; DR, duration response.